Abstract 1397: Serum Vaspin Levels Are Positively Associated With Cardiometabolic Risks in a General Population
[Objective] Recently, visceral adipose tissue-derived serine protease inhibitor (vaspin) has been identified as a novel adipocytokine with potentially insulin-sensitizing properties. In humans investigators reported that elevated vaspin levels were associated with obesity and insulin resistance. However, the elevation of vaspin may be secondary to obesity. Therefore, we investigated the relationships between serum vaspin levels and BMI or insulin resistance without obesity in a general population.
[Methods] A total of 226 subjects (86 men and 140 women) of a general population (mean BMI<24kg/m2) received a health examination in Uku-town, Nagasaki prefecture. We measured serum vaspin concentrations by ELISA and the components of METs (waist, BMI, blood pressure, fasting plasma glucose, lipid profiles, and insulin levels). Uni- and multivariate analyses for correlates of vaspin were performed.
[Results] Mean vaspin levels were 0.78±0.02 ng/ml. Age- and sex- adjusted vaspin levels were positively associated with BMI (p<0.05), insulin (p<0.05), HOMA (the homeostasis model assessment index (p<0.01), triglycerides (p<0.05), creatinine (p<0.01), and uric acid (p<0.05). Serum vaspin levels stratified by tertiles of HOMA showed a positive significant trend (p=0.001 for trend) after adjustments for age, sex, and BMI.
[Conclusions] The present study showed that serum levels of vaspin were associated with insulin resistance in subjects without obesity. Our results may suggest that vaspin is closely related to glucose metabolism in humans.